Research Analysts Offer Predictions for CorMedix Q1 Earnings

CorMedix Inc (NASDAQ:CRMD) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for CorMedix in a research note issued to investors on Friday, January 23rd. HC Wainwright analyst B. Folkes forecasts that the company will post earnings of $0.73 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for CorMedix’s FY2030 earnings at $2.47 EPS.

CorMedix (NASDAQ:CRMD) last posted its earnings results on Wednesday, November 12th. The company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.78. The business had revenue of $104.28 million during the quarter, compared to analyst estimates of $65.63 million. CorMedix had a return on equity of 51.77% and a net margin of 75.83%.The company’s quarterly revenue was up 810.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.05) EPS.

Several other research firms also recently weighed in on CRMD. Needham & Company LLC lowered their target price on CorMedix from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Truist Financial set a $16.00 price objective on CorMedix in a research report on Thursday, January 8th. Weiss Ratings reissued a “hold (c)” rating on shares of CorMedix in a report on Wednesday, January 21st. Wall Street Zen downgraded CorMedix from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, D. Boral Capital restated a “buy” rating and issued a $14.00 target price on shares of CorMedix in a report on Thursday, January 8th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $15.86.

CorMedix Stock Performance

Shares of CRMD opened at $7.76 on Monday. CorMedix has a one year low of $5.60 and a one year high of $17.43. The firm has a market capitalization of $611.41 million, a P/E ratio of 3.77 and a beta of 1.36. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.94 and a quick ratio of 1.73. The business has a fifty day moving average of $10.10 and a 200 day moving average of $11.19.

Insiders Place Their Bets

In related news, Director Alan W. Dunton sold 20,000 shares of the stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $13.00, for a total value of $260,000.00. Following the completion of the transaction, the director directly owned 40,250 shares of the company’s stock, valued at $523,250. This trade represents a 33.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Joseph Todisco sold 30,000 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $12.00, for a total transaction of $360,000.00. Following the completion of the transaction, the chief executive officer directly owned 509,496 shares of the company’s stock, valued at approximately $6,113,952. This represents a 5.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 90,000 shares of company stock worth $1,095,200. 3.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CorMedix

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Marshall Wace LLP grew its position in CorMedix by 34.6% during the 3rd quarter. Marshall Wace LLP now owns 3,473,494 shares of the company’s stock worth $40,397,000 after purchasing an additional 893,518 shares during the period. Deerfield Management Company L.P. purchased a new stake in shares of CorMedix during the third quarter worth about $38,656,000. Geode Capital Management LLC raised its holdings in shares of CorMedix by 11.4% during the second quarter. Geode Capital Management LLC now owns 1,596,322 shares of the company’s stock valued at $19,669,000 after acquiring an additional 163,403 shares during the last quarter. Alyeska Investment Group L.P. lifted its holdings in CorMedix by 68.4% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,262,979 shares of the company’s stock valued at $14,688,000 after purchasing an additional 512,979 shares in the last quarter. Finally, UBS Group AG grew its stake in CorMedix by 295.3% during the 3rd quarter. UBS Group AG now owns 1,090,908 shares of the company’s stock valued at $12,687,000 after acquiring an additional 814,964 shares in the last quarter. Institutional investors and hedge funds own 34.18% of the company’s stock.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.